Pharmaceutical Bio Association Hosts 'KPBMA-MIT Life Sciences Conference'

Sharing the Latest Insights in Oncology and Neurology from MIT and Leading Korean Scholars

KPBMA-MIT Life Sciences Conference Poster.

[Asia Economy Reporter Lee Gwan-ju] Leading global scholars in the pharmaceutical and biotechnology fields, representatives from the United States' premier industry-academia collaboration programs, and local pharmaceutical and biotech startups will gather in one place.

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on the 25th that it will hold the ‘KPBMA-MIT Life Sciences Conference (LSC)’ over two days from March 31 to April 1, targeting domestic and international pharmaceutical and biotech industry stakeholders.

The LSC, now in its second year, was established to promote 'open innovation' in the industry by introducing the latest research trends from the Massachusetts Institute of Technology (MIT) and innovative technologies from MIT spin-off startups.

Focusing on the fields of ‘Oncology’ and ‘Neurology/CNS,’ this event features presentations by world-renowned experts in each area. On the first day of the conference, March 31, lectures include ▲Cancer immunology research using genetically mutated mouse models (Professor Tyler Jacks, MIT) ▲Accelerating new drug development through translational research (Professor Ko Young-il, Seoul National University Hospital).

Following these, presentations by MIT-affiliated startups will cover topics such as ▲Modulus Discovery, illuminating the future of drugs (Roy Kimura, CEO of Modulus Discovery) ▲Accelerating new drug development through well-organized research and science (tentative title, Andrew Radin, CEO of Aria Pharmaceuticals) ▲CareAcross, a bridge connecting cancer patients worldwide (Thanos Kosmidis, CEO of CareAcross).

On April 1, presentations will include ▲Neuro-immune interactions generating social behavior (Professor Gloria Choi, MIT) ▲Reversal of motor disorders by T-type calcium channel blockade using antisense oligonucleotides (ASO) (Professor Kim Dae-su, KAIST). Additionally, talks will cover ▲Innovative therapies for neurological diseases (Jaspal Singh, CEO of Interon Labs) ▲Soft implantable brain-machine interfaces (Paul Le Floch, CEO of Asoft) ▲Kinobi, a biophysical frontier accelerating drug development (Joseph Azarelli, CEO of Kinobi).

Won Hee-mok, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, stated, “This conference brings together world-class scholars and companies with innovative technologies. Through continuous exchange with the MIT innovation ecosystem, the association will identify cutting-edge trends in the pharmaceutical and biotech industries and actively promote open innovation activities.”

This content was produced with the assistance of AI translation services.